Details checkedStrong evidenceCheckedtrial

NS101 by Neuracle Science

Also known as: NS101, Anti-FAM19A5 antibody

Neuracle Science Co., Ltd.

Primary source

Company

Neuracle Science Co., Ltd.

Program Type

Therapeutic

Modality

Biologic

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Systemic infusion

Confidence

92%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-06-08

Geography

South Korea

Population

adult, sudden, sensorineural, salvage-therapy

Trial IDs

Mechanism

Systemic monoclonal antibody targeting FAM19A5, intended to promote synaptic reconnection and recovery in sudden sensorineural hearing loss after insufficient response to steroid therapy.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss Cochlear Synaptopathy

Notes

Verified active Neuracle Science hearing-loss program. The registry describes a Phase 1b/2a placebo-controlled study in healthy volunteers and sudden sensorineural hearing loss patients, and Neuracle describes NS101 as an anti-FAM19A5 monoclonal antibody relevant to sensorineural hearing loss synaptopathy.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, company, stage, status, route, indications, populationTags, geography...

IDs: NCT06249919, NS101, FAM19A5

Open

company

Supports: company, modality, mechanism, indications, notes

IDs: NS101, FAM19A5

Open

company

Supports: status, indications, notes